Insider Buying: Attovia Therapeutics (NASDAQ:ATTO) Major Shareholder Acquires 200,000 Shares of Stock

Attovia Therapeutics, Inc. (NASDAQ:ATTO) major shareholder Redmile Group, Llc acquired 200,000 shares of the company’s stock in a transaction that occurred on Thursday, August 6th. The stock was acquired at an average price of $17.00 per share, with a total value of $3,400,000.00. Following the acquisition, the insider owned 982,854 shares in the company, valued at $16,708,518. The trade was a 25.55% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Redmile Group, Llc also recently made the following trade(s):

• On Thursday, August 6th, Redmile Group, Llc bought 400,000 shares of Attovia Therapeutics stock. The shares were acquired at an average cost of $17.00 per share, for a total transaction of $6,800,000.00.

Attovia Therapeutics Stock Performance

ATTO stock opened at $20.17 on Monday. Attovia Therapeutics, Inc. has a 52-week low of $18.64 and a 52-week high of $22.79.

Hedge Funds Weigh In On Attovia Therapeutics

An institutional investor recently raised its position in Attovia Therapeutics stock. BlackRock Inc. raised its position in Attovia Therapeutics, Inc. (NASDAQ:ATTO) by 23.4% during the second quarter, according to its most recent filing with the SEC. The firm owned 164,358 shares of the company’s stock after purchasing an additional 31,189 shares during the period. BlackRock Inc.’s holdings in Attovia Therapeutics were worth $317,000 as of its most recent filing with the SEC.

Attovia Therapeutics Company Profile

Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company’s research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs.

Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways.